Contineum Therapeutics, Inc. (CTNM) Stock Price & How to Invest

Contineum Therapeutics, formerly Pipeline Therapeutics, is a San Diego biotech that listed on the Nasdaq in April 2024 through an IPO priced at $16 a share that raised ~$110 million. It develops oral small-molecule drugs for fibrotic, inflammatory and neurological diseases, and it has no approved products. The lead program is PIPE-791, a once-daily oral antagonist of the LPA1 receptor, a lipid-signalling receptor tied to the scarring that drives IPF. PIPE-791 is in PROPEL-IPF, a global, randomized, placebo-controlled Phase 2 trial of ~324 patients whose primary endpoint is the change in forced vital capacity (FVC, how much air a patient can exhale) over 26 weeks. The second asset, PIPE-307, a selective M1 muscarinic receptor inhibitor, is licensed to Johnson & Johnson, which paid $50 million upfront in 2023, bought $25 million of stock, and owes up to ~$1.0 billion in milestones plus royalties if it succeeds. The company makes money today only from interest on its cash.

Two pieces of news reshaped the stock in a month. On September 14, 2026, Contineum said J&J's Phase 2 MOONLIGHT-1 trial of PIPE-307 (JNJ-5120) in 107 adults with major depressive disorder missed its primary endpoint, the change in MADRS depression score at Day 5 versus placebo. That followed Contineum's own VISTA trial of PIPE-307 in relapsing multiple sclerosis, which missed in 2025. Then on October 12, Bristol Myers Squibb reported that its LPA1 antagonist admilparant met the primary endpoint of the ~1,255-patient Phase 3 ALOFT-IPF trial at 60 mg twice daily but did not reach statistical significance at 120 mg. CTNM closed that day down ~36% at ~$8.57, near its 52-week low of ~$8.43 and about half its ~$17.79 high. In the second quarter the net loss was ~$15.2 million, with research spending down 10% to ~$12.7 million after a smaller discovery effort and a research workforce cut.

The investment debate now turns on one question: does the admilparant result validate PIPE-791 or simply put a larger rival years ahead? With ~37.6 million shares, the market value is ~$320 million against ~$236.6 million of cash and securities at June 30, which management says funds operations into mid-2029, about a year past PROPEL-IPF's estimated completion in June 2028. Supporters point to a class that now has Phase 3 proof, a claimed potency and once-daily dosing edge, and a share price largely backed by cash. Skeptics point to the dose-response puzzle in ALOFT-IPF, a single-asset pipeline after two PIPE-307 misses, and a long wait for data.

The central risk is binary: if PROPEL-IPF does not show a meaningful FVC benefit, the stock has little to support it beyond cash, and that cash falls by roughly ~$60 million a year. Even with positive data, admilparant is a Phase 3 asset backed by a large pharma company heading toward filings, so it would likely reach patients years before PIPE-791. The IPF market already includes Boehringer Ingelheim's Ofev (nintedanib), generic pirfenidone and Boehringer's newer nerandomilast, so a late entrant needs clear differentiation on efficacy, tolerability or convenience. PIPE-307 has now missed in two Phase 2 trials (multiple sclerosis in 2025 and depression in 2026), and J&J alone decides whether to continue, so the milestone stream could disappear. The research workforce cut and the departure of the chief scientific officer narrow the pipeline behind PIPE-791. The stock is small and highly sensitive to peer news, as the ~36% one-day fall on a competitor's trial showed, and any Phase 3 would almost certainly need new financing or a partner, which could dilute existing holders.

7 analysts publish price targets on CTNM, averaging $22.14 against a $7.08 price as of October 2026, or +212.7%. The published targets run from $14.00 to $30.00, a wide spread, and the ratings split 6 buy, 2 hold, 0 sell. Over the last six months there have been 3 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CTNM forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Contineum Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The PROPEL-IPF readout for PIPE-791. Nearly all of Contineum's value rests on this ~324-patient Phase 2 trial, which compares PIPE-791 with placebo on lung-function decline over 26 weeks. The most optimistic published target, $30.00, assumes this works close to its best case.

The case against. The central risk is binary: if PROPEL-IPF does not show a meaningful FVC benefit, the stock has little to support it beyond cash, and that cash falls by roughly ~$60 million a year. The most pessimistic target, $14.00, is roughly what CTNM is worth if this bites instead.

Read the full bull and bear case on CTNM, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Contineum Therapeutics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$0 (no product or collaboration revenue reported in 2026)
• Net loss (Q2 2026): ~$15.2 million (vs ~$16.0 million in Q2 2025)
• R&D expense (Q2 2026): ~$12.7 million (down 10% year over year)
• Cash and marketable securities: ~$236.6 million (June 30, 2026)
• Market capitalization: ~$320 million (~37.6 million shares, ~$8.57 on Oct 12, 2026)
• Cash runway (company guidance): Into mid-2029

Contineum has no sales and loses money, so price-to-earnings and price-to-sales ratios do not apply. The useful comparison is market value against cash. After the October 12 fall, the enterprise value (market value minus cash) is roughly ~$85 million to ~$100 million, and that is what the market assigns to PIPE-791, the J&J milestones and everything else combined. Price to book is ~1.3, which says the same thing. The next scheduled update is third-quarter results, which should show the cash balance and any word from J&J on PIPE-307.

Other names that sit close to CTNM: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CTNM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CTNM sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CTNM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Contineum is a pre-revenue, single-asset IPF story priced not far above its cash, so the outcome rests on whether PIPE-791 can match or beat what Bristol Myers Squibb's admilparant showed.

Whether CTNM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CTNM a buy or a sell?, and where the stock could go from here in the CTNM stock forecast.

For income investors, whether CTNM pays a dividend and how the payout looks is covered in does CTNM pay a dividend? And to weigh CTNM against a peer, read the full side-by-side comparisons: CTNM vs BMY and CTNM vs JNJ.